Cereno Scientific strengthens patent protection for Phase II drug candidate CS1 across two patent families
Cereno Scientific today announced that the intellectual property rights (IPR) for drug candidate CS1 have been expanded in two different patent families. The patent granted in Canada belongs to the company’s first patent family, and the patent granted in Russia belongs to the company’s second patent family. This is a result of Cereno’s continuous work in securing IPR for its assets to strengthen the commercial positioning.“Working to continuously strengthen our IPR around our drug candidates and technology is an important part of our strategy aimed at optimally positioning Cereno for